Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02393625 · ClinicalTrials.gov registry record · Phase 1
Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer
A Phase 1 study of ALK-positive NSCLC, sponsored by Novartis Pharmaceuticals.
- Active
- Registry status
- Phase 1
- Development phase
- 57
- Enrollment target
- 12
- Study locations
NCT02393625 is a Phase 1 study of ALK-positive NSCLC that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 57 participants. The trial reports 12 study locations across 9 states.
The verdict
NCT02393625, a Phase 1 study of ALK-positive NSCLC, is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 57 participants
- Enrollment target
- 12
- Study locations
Study Summary
This is an open label multi center trial to determine the safety and efficacy of ceritinib in combination with nivolumab in ALK-positive NSCLC patients
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Ceritinib (LDK378)
Study Locations (12)
Other
- Novartis Investigative Site - Hong Kong
- Novartis Investigative Site - Singapore
- Novartis Investigative Site - Barcelona
Massachusetts
- Massachusetts General Hospital - Boston
- Massachusetts General Hospital Thoracic Oncolgoy - Boston
Arizona
- Mayo Clinic - Arizona - Scottsdale
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Victoria
- Novartis Investigative Site - Heidelberg
Vlaams Brabant
- Novartis Investigative Site - Leuven
Ontario
- Novartis Investigative Site - Toronto
MI
- Novartis Investigative Site - Milan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2015-05-27 |
| Est. Completion | 2027-04-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02393625
The ClinicalTrials.gov registry entry for NCT02393625 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with ALK-positive NSCLC appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.
NCT02393625 reports 12 study locations spanning 9 distinct geographic areas - top geographies include Other, Massachusetts, Arizona.
Frequently Asked Questions
What is clinical trial NCT02393625 about?
NCT02393625 is a clinical study titled "Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer". This is an open label multi center trial to determine the safety and efficacy of ceritinib in combination with nivolumab in ALK-positive NSCLC patients
What is the current status of trial NCT02393625?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 57 participants. The study started on 2015-05-27. Estimated completion is 2027-04-09.
What conditions does trial NCT02393625 study?
This clinical trial studies the following conditions: ALK-positive NSCLC.
What interventions are being tested in trial NCT02393625?
The interventions under investigation include: Nivolumab (DRUG), Ceritinib (LDK378) (DRUG).
Who is sponsoring clinical trial NCT02393625?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02393625 being conducted?
This trial has 12 study locations across Arizona, Massachusetts, Pennsylvania, Victoria, Vlaams Brabant. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.